| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0002 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0004 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.18 | 0.0007 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0007 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0007 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |